香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其 準確性或完備性亦無發表聲明，並表明不會就本公告全部或任何部份內容或因倚賴該等 內容而引致之任何損失承擔任何責任。 China Health Group Inc. 香港，二零二五年八月十三日 於本公告日期，董事會成員包括两名執行董事，分別為郭夏先生及郭瑞萌先生；一名非 執行董事，為張麗博士；及四名獨立非執行董事，分別為倪彬暉博士、伍霜駟先生、郭 彤博士及劉娜女士。 本公告載有根據 GEM 上市規則規定須提供有關本公司資料的詳情，董事願就本公佈共同 及個別地承擔全部責任。各董事在作出一切合理查詢後確認，就彼等所知及所信，本公 佈所載的資料在各重大方面乃準確完整,無誤導或欺詐成份，且概無遺漏任何其他事宜 致使本公佈或其所載任何陳述產生誤導。 本公告將於联交所網址 www.hkexnews.hk 之「最新上市公司公告」網頁刊載，由刊載日 期起計為期七日，並於本公司網址 http://www.chgi.net 網頁刊載。 中國醫療集團有限公司 （以「萬全醫療集團」名稱在香港經營業務） (於開曼群島註冊成立之有限公司) (股份代號: 08225 ...

呈交日期: 2025年8月6日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 08225 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 10,000,000,000 | HKD | | 0.1 HKD | | 1,000,000,000 | | 增加 / 減少 (-) | | | 0 | | | HKD | | 0 | | 本月底結存 | | | 10,000,000,000 | HKD | | 0.1 HKD | | 1,000,000,000 | FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年7月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 中國醫療集團有限公司 (以「萬全醫療集團」名稱 ...

金十期货7月29日讯，伦敦金属交易所（LME）有色金属注册及注销仓单如下： 1. 铜注册仓单108225吨，注销仓单19400吨，增加2125吨。 2. 铝注册仓单441600吨，注销仓单14500吨，减少475吨。 3. 镍注册仓单195396吨，注销仓单9516吨，减少306吨。 4. 锌注册仓单57600吨，注销仓单54550吨，减少400吨。 5. 铅注册仓单198450吨，注销仓单71900吨，减少1025吨。 6. 锡注册仓单1350吨，注销仓单505吨，增加175吨。 LME注册及注销仓单日报 ...

Core Viewpoint - The Chinese medical group industry is experiencing rapid development and strategic transformation, with a projected revenue of 40.5 billion yuan in 2024, reflecting a year-on-year growth of 27.52%, indicating strong market expansion momentum [1][13]. Industry Overview - Medical groups, also known as "medical practice organizations," consist of multiple doctors forming alliances or independent legal entities, sharing income and risks while providing medical services [2]. - The industry includes internal, external, and cross-system medical groups based on the attributes of the doctors involved [2]. Industry Development History - The industry has gone through three main phases: 1. **Incubation Period (1996-2013)**: The first medical group was established in 1996, but growth was slow due to policy constraints [4]. 2. **Rapid Development (2014-2018)**: The introduction of supportive policies led to a surge in medical groups, with over 1,000 established by 2018 [4]. 3. **Rational Adjustment (2019-Present)**: The industry faced challenges due to increased competition and capital constraints, leading to a focus on online and offline integration [5][6]. Industry Current Status - The industry is in a critical phase of rapid growth and strategic transformation, with significant capital inflow and innovative competition models emerging [1][13]. - Leading institutions like the Ludaopei Medical Group have completed substantial financing, reflecting high market recognition for medical resource integration platforms [1][13]. Industry Value Chain - The upstream of the medical group industry includes medical equipment, pharmaceuticals, medical technology, and human resources, while the downstream consists of patients who receive medical services [8]. Industry Development Trends 1. **Technological Drive and Digital Transformation**: The industry will accelerate the adoption of AI, big data, and telemedicine, creating a blended online and offline healthcare system [21]. 2. **Market Demand Upgrade**: There will be a growing demand for personalized medical services and health management, leading to diversified service models [22]. 3. **Policy Support for Standardization**: Government policies will encourage the development of medical groups, enhancing operational capabilities and brand building [23]. Key Group Profiles - **Zhang Qiang Medical Group**: Established in 2014, focusing on vascular surgery, it has become a pioneer in the industry with multiple specialized teams [15][17]. - **Harteim Heart Medical Group**: Founded in 2015, it specializes in cardiovascular diseases and has established a comprehensive service network across China [15][19]. - **Ludaopei Medical Group**: Focused on hematology, it has rapidly expanded its services nationwide and achieved significant financing [15][17].

2024 CHINA HEALTH GROUP INC. 中國醫療集團有限公司 (Carrying on business in Hong Kong as "萬全醫療集團") (以「萬全醫療集團」名稱在香港經營業務) (Incorporated in the Cayman Islands with limited liability) (於 開 曼 群 島 註 冊 成 立 之 有 限 公 司) (Stock Code: 08225) (股份代號: 08225) ANNUAL REPORT FOR THE YEAR ENDED 31 DECEMBER 2024 截至二零二四年十二月三十一日止 之年度報告 CHARACTERISTICS OF GEM OF THE STOCK EXCHANGE OF HONG KONG LIMITED (THE "STOCK EXCHANGE") GEM has been positioned as a market designed to accommodate small and mid-sized companies to which a higher investment ...

Financial Performance - For the year ended December 31, 2024, China Health Group Inc. reported revenue of RMB 26,454,000, an increase of 23.3% from RMB 21,425,000 in 2023[10] - The gross profit for the year was RMB 10,067,000, representing a gross margin of approximately 38.0%, compared to RMB 8,212,000 in 2023[10] - The net loss for the year was RMB 14,519,000, significantly reduced from a loss of RMB 58,211,000 in 2023, indicating an improvement of 75.0%[10] - The basic and diluted loss per share improved to RMB 1.46 from RMB 5.83 in 2023, showing a reduction of 75.0%[10] - Loss before taxation for 2024 was RMB 14,519,000, an improvement from a loss of RMB 58,014,000 in 2023[74] - The Group reported a loss before tax of approximately RMB14,473,000 for 2024, significantly reduced from a loss of approximately RMB58,211,000 in 2023[88] - Net loss for the year was approximately RMB14,519,000, compared to a net loss of approximately RMB58,211,000 in 2023[88] Cash and Liquidity - As of December 31, 2024, the Group had cash and cash equivalents of approximately RMB 14,194,000 against current liabilities of approximately RMB 31,243,000, indicating liquidity pressure[14] - The Group's net current assets as of 31 December 2024 were approximately RMB61,393,000, down from approximately RMB77,014,000 in 2023[94] - The Group's total asset-liability ratio remained at 0% as there were no borrowings in both 2023 and 2024[100] - The Group's gearing ratio was nil as of 31 December 2024, indicating no borrowings during the year[95] - The directors believe the Group can finance its operations and meet financial obligations within the forecast period based on cash flow projections[21] - There exists material uncertainty regarding the Group's ability to continue as a going concern due to the financial situation[22] Revenue Sources - Revenue from post-market services increased to RMB 26,454,000 in 2024, up from RMB 17,500,000 in 2023, representing a growth of 51.4%[56] - Total revenue from contracted clinical research services decreased to RMB 0 in 2024, down from RMB 3,925,000 in 2023[56] - Revenue from post-marketing research and academic extension services accounted for approximately 100% of total revenue in 2024, up from 82% in 2023[87] Expenses and Cost Management - Administrative expenses increased to RMB 10,076,000 from RMB 7,606,000, representing a rise of 32.4%[10] - Staff costs decreased to RMB 3,772,000 in 2024 from RMB 4,549,000 in 2023, reflecting a reduction of 17%[68] - Total consolidated administrative expenses for 2024 were approximately RMB24,912,000, down from approximately RMB66,543,000 in the previous year[89] Trade Receivables - Trade receivables from related companies amounted to approximately RMB 48,186,000, with an agreement to settle RMB 18,000,000 during the year ending December 31, 2025[15] - The company reported a significant expected credit loss on trade receivables amounting to RMB 14,807,000 in 2024, down from RMB 57,937,000 in 2023[68] - Approximately RMB32,000,000 of trade receivables were recovered in 2024, while approximately RMB36,000,000 of long-aged trade receivables remain outstanding[90] Business Strategy and Development - The Group is actively controlling operating costs and expects to generate positive cash flows from operations in the foreseeable future[15] - The Group has focused on three major disease areas: brain science, allergies, and viruses, establishing five major specialty brands: Xixin mental psychology, Baimin anti-allergy, Yuejie addiction, Jianshou Anti-Dementia, and Rare Diseases[175] - The Group's strategy has shifted from drug development services to big data and post-marketing clinical research treatment and commercial promotion of five core diseases over the past seven years[175] - The Group aims to build digital research and development clinical research specialties, along with special specialty medical drug clinics and rehabilitation medical services[178] Future Outlook - The Group plans to raise further funds through various means such as bank loans and issuance of new debts to enhance capital reserves for future business development[100] - The directors have a reasonable expectation that the Group has adequate resources to continue operational existence for the foreseeable future[24] - The Group is committed to building a comprehensive medical terminal service complex supported by intelligent digital technology, forming a closed-loop system from research to rehabilitation and cure[178] Corporate Governance and Compliance - The consolidated financial statements have been prepared on a going concern basis[25] - The Group's consolidated financial statements for the year ended December 31, 2024, were reviewed by the Audit Committee and comply with applicable accounting standards[150] - The Group has adopted a share option scheme for eligible participants, enhancing employee engagement and retention[137] Research and Innovation - The Group has actively laid out in the field of artificial intelligence, particularly enhancing competitiveness through the comprehensive layout of Deepseek technology and establishing new companies in Hainan and the Guangdong-Hong Kong-Macao Greater Bay Area[160] - The establishment of digital specialty clinics in collaboration with top medical institutions is underway, enhancing the Group's service offerings[111] - The "RWS Wanquan Center" aims to re-screen existing drugs using big data to find optimal treatments for diseases like stroke and COPD[110]

Financial Performance - For the six months ended June 30, 2024, the group recorded revenue of approximately RMB 18,293,013, an increase of about 21.75% compared to RMB 15,024,938 for the same period in 2023[2] - The group reported a profit before tax of approximately RMB 8,651,000, up approximately 26.22% from RMB 6,854,000 in the same period of 2023[2] - Gross profit for the six months ended June 30, 2024, was RMB 11,982,000, with a gross margin of approximately 65.5%, compared to a gross profit of RMB 9,686,000 and a gross margin of 65% in the same period of 2023[2] - The net profit attributable to the owners of the company for the six months ended June 30, 2024, was RMB 7,353,000, compared to RMB 5,826,000 for the same period in 2023[7] - Basic and diluted earnings per share for the six months ended June 30, 2024, were both 0.74 cents, compared to 0.60 cents for the same period in 2023[7] - The total revenue for the six months ended June 30, 2024, increased by 21.75% compared to the same period in 2023, with PMS revenue also rising by approximately 21.75%[23] - The group reported a net profit attributable to owners of the company of approximately RMB 7,353,000 for the period, compared to RMB 5,826,000 in 2023, indicating a significant increase in earnings[25] - Net profit for the current period was approximately RMB 7,353,000, representing a 26.21% increase from RMB 5,826,000 in the previous year[34] Cash Flow and Assets - Net cash generated from operating activities was RMB 2,883,000, compared to RMB 1,164,000 for the same period in 2023[17] - The total assets as of June 30, 2024, amounted to RMB 120,196,000, an increase from RMB 112,180,000 as of December 31, 2023[16] - The net current assets as of June 30, 2024, were RMB 83,006,000, compared to RMB 77,014,000 as of December 31, 2023[16] - The cash and cash equivalents at the end of the period were RMB 6,858,000, an increase from RMB 4,534,000 at the end of the same period in 2023[17] - The company's net current assets and net assets as of June 30, 2024, were approximately RMB 83,006,000 and RMB 91,536,000, respectively, compared to RMB 77,014,000 and RMB 84,183,000 as of December 31, 2023[34] Dividends and Shareholder Information - The board of directors recommended not to declare any dividends for the six months ended June 30, 2024[2] - The group did not recommend any dividend payment for the period, consistent with the previous year[27] - The board does not recommend the distribution of dividends for the six months ending June 30, 2024, consistent with the previous year[37] - The major shareholder Winsland Agents Limited holds 349,368,873 shares, representing 35.10% of the total[53] - The total number of shares held by the beneficial owner Guo Xia is 132,851,941, which accounts for 13.35% of the total[51] - The beneficial ownership of Bright Excel Assets Limited is 91,915,181 shares, which is 9.23% of the total[53] Corporate Governance - The company has adopted corporate governance practices based on the GEM Listing Rules, emphasizing board quality, transparency, and accountability to shareholders[68] - The company has complied with the trading standards and codes of conduct regarding securities transactions by its directors during the reporting period[69] - The audit committee consists of four independent non-executive directors, ensuring compliance with applicable accounting standards and requirements[70] - The board of directors includes two executive directors and four independent non-executive directors, reflecting a balanced governance structure[71] Operational Focus and Strategy - The group aims to become a comprehensive service provider under an internet architecture in the healthcare sector[19] - The company is focusing on becoming a leader in real-world clinical research services, particularly in five key areas: mental health, neurological diseases, allergic diseases, rare diseases, and viral infections[33] - The company has established a biorepository testing laboratory to support clinical research, particularly for antiviral drug studies[34] - The company is experiencing strong demand for its post-marketing clinical research services, contributing to steady business growth[33] - The company is focusing on clinical research services for traditional Chinese medicine, which is projected to be a market worth over 1 trillion RMB due to the need for re-registration of over 40,000 drug approvals[36] - The company aims to leverage its advantages in Hainan, where it plans to utilize the region's free trade zone status by 2025 to acquire new clients[35] Employee and Compensation Information - The total number of employees as of June 30, 2024, is 41, with total salaries for employees and directors during the period amounting to approximately RMB 2.28 million, an increase from RMB 1.83 million in the same period last year[49] Financial Policies and Risks - The company has no borrowings as of June 30, 2024, and plans to consider raising funds through bank loans, issuing new shares, convertible bonds, or new debt to meet long-term funding needs[34] - The company is closely monitoring foreign exchange risks, with most transactions denominated in RMB[43] - The company has no major investments or capital commitments as of June 30, 2024, maintaining a cautious financial policy[38][39] - The company has not engaged in any significant acquisitions or disposals of subsidiaries or associates during the reporting period[40] - The company has implemented measures to prevent similar financial assistance situations, including enhancing internal supervision and risk assessment processes[32] Stock Options and Incentives - The stock option plan was approved on June 30, 2015, with a validity of 10 years, aimed at incentivizing qualified participants[56] - The stock option exercise price must not be lower than the highest of three specified prices, ensuring fair valuation[58] - The total number of shares available for issuance under the share option plan is 88,947,166 shares, representing 8.94% of the total issued shares as of the interim results announcement date[60] - The maximum number of shares that can be issued upon the exercise of options granted to each eligible participant in any 12-month period is limited to 1% of the issued shares, unless approved by shareholders[60] - The total number of options granted during the specified period is 25,500,000, with a remaining balance of 25,380,000 options as of June 30, 2024[66] - The company has not set any performance targets that must be met prior to the exercise of options, unless decided by the board[61] - There is no minimum holding period required before exercising options under the share option plan, unless determined by the board[62]

1 CHINA HEALTH GROUP INC. 中國醫療集團有限公司 （以「萬全醫療集團」名稱在香港經營業務） (於開曼群島註冊成立之有限公司) (股份代號: 08225) 二零二四年中期業績公告 截至二零二四年六月三十日止六個月 香港聯合交易所有限公司（「聯交所」）GEM 的特色 GEM 之定位，乃為相比起其他在聯交所上市之公司帶有較高投資風險之公司提供一個上市 之市場。有意投資之人士應瞭解投資於該等公司之潛在風險，並應經過審慎周詳之考慮後方作出投 資決定。GEM 之高風險及其他特色表示 GEM 較適合專業及其他經驗豐富投資者。 由於 GEM 上市公司之新興性質，在 GEM 買賣之證券可能會較於主機板買賣之證券承受較 大之市場波動風險，同時無法保證在 GEM 買賣之證券會有高流通量之市場。 香港交易及結算所有限公司及聯交所對本公佈之內容概不負責，對其準確性或完整性亦不發表 任何聲明，並明確表示概不就因本公佈全部或任何部分內容而產生或因倚賴該等內容而引致之 任何損失承擔任何責任。 本公佈乃遵照聯交所 GEM 證券上市規則之規定而提供有關中國醫療集團有限公司（「本公 司」） 之資料，本公司各董事（「董事」） ...

2023 CHINA HEALTH GROUP INC. 中國醫療集團有限公司 (Carrying on business in Hong Kong as "萬全醫療集團") (以「萬全醫療集團」名稱在香港經營業務) (Incorporated in the Cayman Islands with limited liability) (於 開 曼 群 島 註 冊 成 立 之 有 限 公 司) (Stock Code: 08225) (股份代號: 08225) ANNUAL REPORT FOR THE YEAR ENDED 31 DECEMBER 2023 截至二零二三年十二月三十一日止 之年度報告 CHARACTERISTICS OF GEM OF THE STOCK EXCHANGE OF HONG KONG LIMITED (THE "STOCK EXCHANGE") GEM has been positioned as a market designed to accommodate small and mid-sized companies to which a higher investment ...

Financial Performance - For the year ended December 31, 2023, China Health Group Inc. reported revenue of RMB 21,425,000, an increase of 63.6% compared to RMB 13,090,000 in 2022[10]. - The gross profit for the year was RMB 8,212,000, representing a gross margin of approximately 38.3%[10]. - The company incurred a loss before taxation of RMB 58,211,000, compared to a loss of RMB 15,826,000 in the previous year, indicating a significant increase in losses[10]. - Basic and diluted loss per share for the year was RMB 5.83, compared to RMB 1.59 in 2022, reflecting a deterioration in financial performance[10]. - Loss before taxation for 2023 was RMB 58,014,000, compared to a loss of RMB 15,826,000 in 2022[44]. - The Group recorded a loss before tax of approximately RMB 58,211,000 for the year, compared to a loss of approximately RMB 15,826,000 in the same period last year[57]. - The Group incurred a net loss of approximately RMB 58,211,000 for the year ended December 31, 2023, with cash and cash equivalents of only approximately RMB 4,140,000 and current liabilities of approximately RMB 35,166,000[141]. Assets and Liabilities - Non-current assets increased to RMB 7,169,000 in 2023 from RMB 1,399,000 in 2022, indicating investment in long-term assets[12]. - Current assets decreased to RMB 112,180,000 in 2023 from RMB 177,226,000 in 2022, primarily due to a reduction in trade and bills receivables[12]. - Net current assets fell to RMB 77,014,000 in 2023, down from RMB 140,484,000 in 2022, highlighting liquidity challenges[12]. - Total equity attributable to owners of the company decreased to RMB 84,819,000 in 2023 from RMB 142,322,000 in 2022, reflecting a decline in shareholder value[12]. - The expected credit loss on trade and bills receivables significantly increased to RMB 57,937,000 in 2023 from RMB 7,827,000 in 2022[41]. - As of December 31, 2023, the Group's net current assets were approximately RMB 77,014,000, down from approximately RMB 140,484,000 in 2022[65]. - The gearing ratio was nil as of 31 December 2023, indicating no borrowings during the year[66]. - The Group had no charge on any of its assets as of 31 December 2023[172]. - There were no significant contingent liabilities as of 31 December 2023[173]. Revenue Breakdown - Revenue from post-market services increased to RMB 17,500,000 in 2023 from RMB 13,090,000 in 2022, representing a growth of 33.5%[30]. - Revenue from contracted clinical research services was RMB 3,925,000 in 2023, with no revenue reported in 2022[30]. - Total revenue for 2023 reached RMB 21,425,000, up from RMB 13,090,000 in 2022, marking a significant increase of 63.6%[30]. - Revenue from post-marketing research and academic extension services was about RMB 17,500,000, accounting for approximately 81.68% of the total revenue[56]. Operational Changes and Strategies - The company is focused on expanding its market presence and enhancing its service offerings to improve future performance[6]. - The Group's management responded to significant downward pressure in the domestic drug market by strengthening its professional capacity building, achieving positive results despite reduced investment and halted clinical research[130][144]. - The Group has shifted focus from drug development services to big data and post-marketing clinical research for five core diseases, establishing five major specialty brands[131][145]. - The Group launched two new business models: the "Research-based Therapy RWS-Therapy Model" and the "Digital clinical research-based promotion D-CRCO model," redefining traditional treatment and commercialization approaches[133][147]. - The comprehensive medical terminal service complex aims to create a closed-loop system from research to rehabilitation, supported by intelligent digital technology[134][148]. - The Group is committed to building digital medical capabilities to support a comprehensive service model from research to patient care[134][148]. Employee and Administrative Costs - Staff costs decreased to RMB 4,549,000 in 2023 from RMB 7,516,000 in 2022, a reduction of 39.4%[41]. - The total consolidated administrative expenses, including staff costs, were approximately RMB 66,543,000 for the year, significantly higher than approximately RMB 21,800,000 in the previous year[58]. - The Group's employee costs for the year were approximately RMB 4,549,000, a decrease from RMB 7,516,000 in the previous year, with a total of 42 employees as of December 31, 2023[100][108]. - The Group had 42 employees as of December 31, 2023, a decrease from 47 employees in the previous year[186]. Corporate Governance and Compliance - The Audit Committee reviewed the consolidated financial statements for the year ended December 31, 2023, and confirmed compliance with applicable accounting standards and GEM Listing Rules[122]. - The Group's remuneration policy is based on individual performance, with various benefits provided to employees, including medical and pension contributions[98]. - There were no significant disclosable events after the reporting period[97]. - The Group did not purchase, sell, or redeem any of its listed securities during the year[188]. Future Outlook - The company aims to become a leading anti-allergy center globally, with over 60% of anti-allergy drugs developed by the Baymin Clinical Research Center[78]. - The Group may consider raising further funds through bank loans, issuance of new shares, convertible notes, and issuance of new debts for future development[67]. - The company has established digital medicine clinics in collaboration with top medical institutions across major cities in China[83]. - The Group has established partnerships with top medical institutions in Beijing, Shanghai, and Guangzhou to develop digital specialty clinics, focusing on areas such as smoking cessation and psychological treatment[88].